Connect with us

BUSINESS

Hemp Inc (OTCMKTS: HEMP) Appointed James Hancock As A President

Published

on

Hemp Inc (OTCMKTS: HEMP) is an industry leader in the hemp market and has announced the replacement of Craig Perlowin with James Hancock as a president. On the other hand, Neutra Corp (OTCMKTS: NTRR) announced its product would shortly be available at Mid-West Grocery Chain Flagship Store.

New President to drive business: The company announced the appointment of James Hancock as a president. The company stated that Hancock has lead several organizations from the front and served in a senior position for quite a few companies. He is said to be a turnaround and mergers and acquisition expert. The company feels that James Hancock is an innovative thinker with experience of over 40 years of serving publicly traded companies in financial services, mergers and acquisitions, investment banking, and payment processing solutions. The company feels that Hancock’s expertise will be a good asset for the company to drive growth in the near to medium term. Hancock will be replacing Craig Perlowin, who left the company to pursue its interest and spend more quality time with family.

Neutra Corp (OTCMKTS: NTRR) Product to soon be available in Mid-West: As per the company, its product has been officially accepted by the Mid-West grocery company. The company will sell its product (CBD) initially with the chain flagship location. The company has already submitted its compliance requirements and is waiting to make its products available shortly. As per the management, this is the first of the big-box chains for Neutra and VIVIS. It is expected to open the door for many more opportunities in the time to come. 

The hard work by the company’s sales force to pursue a new market, focus on new segments and venues helped the company to achieve this benchmark. The efforts of Neutra Corp are also be benefitting its wholly-owned subsidiary VIVIS. It further added that its sales force is also in talks with various other retail chains for selling its product in the Mid-Atlantic and Mid-West areas. In addition, the company said that it’s recently acquired Deity Wellness recorded over 2,000 orders for Delta-8-infused gummies, vape cartridges, etc., in just forty-eight hours.

[optin-monster-shortcode id="lt2ftjs5qhrst1pzmmap"] *Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading
Advertisement
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

BUSINESS

Lexaria Bioscience Corp (NASDAQ: LEXX) Expected to Offer Safe, Effective, and Affordable Treatment

Published

on

Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces that the company’s name features in an editorial published by NetworkNewsWire, a trusted brand within the InvestorBrandNetwork. In addition, the company states that they lead the way of innovation in Hypertension Treatment, which is safe and effective.

The company to lead industry in providing affordable treatment

One of the most pervasive diseases in first-world countries is heart disease, one of the leading causes of death for women and men in the United States. As per the industry, one person dies every 36 seconds from cardiovascular disease. According to the CDC (Centers for Disease Control and Prevention), either high blood pressure or hypertension is one of the critical risk factors for heart disease and stroke. The industry also stated that almost 50% of adults in the United States have hypertension. Of which, only ~24% of the hypertension patients have their condition under control. 

The industry needs to find effective treatments for the most pervasive diseases, with many companies leading innovation. Lexaria Bioscience Corp is one company working on innovative medicine, with its patented drug delivery DehydraTECH(TM). The company is joining a group of companies working together to provide safe, effective, and affordable treatment.

Results showing positive development

As per the company, a human clinical study using DehydraTECH technology showed a fast and sustained fall in blood pressure. It is a step forward by the company to treat hypertension, particularly in stage 2 hypertensive volunteers. Initial trial results show that blood pressure declined amongst the adults and was seen within the 10-50 minutes of the study. The results reinforce, DehydraTECH delivers far superior performance over the generic controls. Industry experts also indicated that the results are promising for patients at risk of hypertension and provide fundamental support for expanding clinical trials.

[optin-monster-shortcode id="lt2ftjs5qhrst1pzmmap"] *Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading

BUSINESS

Reliq Health Technologies Inc (OTCMKTS: RQHTF) Signed a New Contract to Provide iUGO Platform

Published

on

Reliq Health Technologies Inc (OTCMKTS: RQHTF) is the fastest growing global telemedicine company, developing innovative Virtual Care solutions for the Healthcare market. In addition, the company announced that they had signed a new contract with six new U.S primary care physician practices for providing its iUGO care platform for their chronic disease patients.

Contract with six new U.S. primary care physician practices

The company entered into a contract with six new U.S primary care physician practices. Moreover, the company added 4,000 new patients to its iUGO care platform. As per the agreement, all the primary care physician practices will be using Reliq Health Technologies iUGO Care RPM (Remote Patient Monitoring), CCM (Chronic Care Management and BHI (Behavioural Health Integration) modules. Reliq’s iUGO Care platform supports care coordination and community-based virtual healthcare monitoring. In addition, the platform also provides real-time access to remote patient monitoring data, timely interventions by the care team to prevent costly hospital readmissions.

The company is likely to report the first full profitable quarter

As per the company, the average revenue from the new contract is likely to be >$40 per patient per month. The company further stated that the onboarding of all the six new physicians is likely to start in the current month and be completed by October. Moreover, the recent client acquisition and patient enrolling are gaining space rapidly since July and are expected to continue strong growth in the coming months. As per the industry, the new physician and enrolling of new patients are expected to support the company revenue starting from October. The significant benefit of the same will come in FY22. The September quarter will be the company’s first full profitable quarter, which is a significant development.

New physicians and over 4,000 new patients give the company strong revenue visibility starting from the current month and significant benefits from November. The higher volume is also expected to support the operating leverage, thereby strengthening the company’s operating performance. However, the industry believes this is just the beginning for the company, and profitability growth is likely to see a sharp increase as the onboarding of the patients increases.

[optin-monster-shortcode id="lt2ftjs5qhrst1pzmmap"] *Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading

BUSINESS

Heritage Cannabis Holdings Corp (OTCMKTS: HERTF) Signs Licensing and Royalty Agreement For Commercialization of Avicanna’s Topical Products

Published

on

Heritage Cannabis Holdings Corp (OTCMKTS: HERTF) has entered an exclusive intellectual property license and royalty agreement with Avicanna Inc. Avicanna is a biopharma company specializing in developing, manufacturing, and marketing plant-based CBD products.

Heritage Cannabis signs licensing agreement with Avicanna

The Agreement is for marketing a range of Avicanna’s advanced CBD-based topical solutions under Heritage medical cannabis brands, aimed towards patients who have registered to acquire medicinal cannabis in Canada.

Avicanna’s patented CBD topical formulations, created over years of rigorous research by the company’s team of scientists, are among the Branded Products to be marketed. The products are all backed up by pre-clinical research, except for two SKUs backed up by completed human trials. Heritage’s broad medical sales channels in Canada will launch the Branded Products in Q4 2021, with the goal of meeting unmet medical requirements in the vast market with scientifically researched and standardized CBD products.

Heritage’s medical division president Umar Syed said, “We are excited to add Avicanna’s innovative topical products to our portfolio of highly effective medical CBD products. They are a great strategic fit. We are very impressed with Avicanna’s diligent R&D approach for developing highly effective topical products formulated with pharmaceutical technology and which are supported with evidence of efficacy, much like the existing Opticann portfolio that includes oral products that use the patented VESIsorb technology and sublingual CBD filmstrips that use the patented Versafilm® technology. The Licensing Agreement offers Heritage speed-to-market with highly effective topicals.”

Avicanna is glad to extend its products to more Canadians

Aras Azadian, Avicanna CEO, commented, “We look forward to collaborating with the Heritage team to extend our proprietary and evidence-based topical formulations to more Canadian patients and expand into more medical channels nationwide. We believe that the alignment of both companies to offer the highest standards for cannabinoid-based medicine and education will yield fruitful and long-term commercial success.”

[optin-monster-shortcode id="lt2ftjs5qhrst1pzmmap"] *Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading

Trending Stories